RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corp. is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition. RXi's first RNAi product candidate, RXI-109, is currently in clinical trials. It targets connective tissue growth factor, a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

Expert Comments:

Keith Markey, Griffin Securities (8/14/15)
"RXi Pharmaceuticals Corp. is focusing on seven initiatives to garner a higher valuation of its technologies and reward its investors. . .we think the initiatives will prove successful in driving the share price in the near term and enhancing the merits of long-term investments in the company's shares. . .this stock carries our Buy rating and a $2.50 price target."

Mark Breidenbach, H.C. Wainwright & Co. (8/13/15)
"We are reiterating our Buy rating of RXi Pharmaceuticals Corp. . .the company has nearly completed two of three Phase 2a trials utilizing optimized RNA interference therapeutics to reduce scarring. . .with a broad portfolio focused on dermal and ophthalmologic indications, multiple data readouts expected later this year and the potential to partner one or more programs, we believe RXi Pharmaceuticals represents an underappreciated innovator with upside for the long-term investor."

Mark Breidenbach, H.C. Wainwright & Co. (6/12/15)
"Earlier this week at the World Congress of Dermatology, RXi Pharmaceuticals Corp. provided updates on the three ongoing Phase 2a studies evaluating RXI-109 in hypertrophic scarring and keloids. Currently, two of the three trials have completed enrollment. . .the third study, dubbed the '1402' trial, has nearly enrolled the first two cohorts (20 patients), and we expect to see three-month results for these cohorts in Q4/15."

Management Q&A: View From the Top
Geert Cauwenbergh

With its unique RNA interference delivery platform, spun out from the mind of a Nobel laureate, CEO Dr. Geert Cauwenbergh describes the transformational treatments RXi Pharmaceuticals Corporation has in its pipeline.
read more >
Keith Markey, Griffin Securities (5/29/15)
"RXi Pharmaceuticals Corp. raised $9.3M via an equity offering yesterday that secured sufficient funds to support operations into 2017 and, hence, to achieve several important valuation-driving milestones in its research and development program. . .the terms of the financing were reasonable. . .our price target is now set at $2.25/share."

Keith Markey, Griffin Securities (4/1/15)
"Investors have overlooked RXi Pharmaceuticals Corp. shares as evidenced by the discrepancy between the company's $15M market capitalization and the status of its drugs in clinical development and the multibillion dollar sales potential of the research and development pipeline. Accordingly, we are affirming our Buy recommendation with a price target of $4.25."

Reni Benjamin, H.C. Wainwright & Co. (3/31/15)
"We are reiterating our Buy rating of RXi Pharmaceuticals Corp. . .the company has three ongoing Phase 2 clinical studies utilizing optimized RNA interference (RNAi) therapeutics, including two in hypertrophic and one in keloid scarring. . .with a proprietary RNAi platform focused on dermal and ophthalmologic applications, a topical immunomodulatory asset with known efficacy in cosmetic indications, and a pro forma cash position of $6.8M, we believe RXi represents an undervalued player with upside for the long-term investor. .yesterday, RXi reported a Q4/14 net loss of ($2.8M), or ($0.13) per share, comparable to our estimate of ($2.8M), or ($0.14) per share."

More Expert Comments

Experts Commenting on This Company

Reni Benjamin, Senior Biotechnology Analyst – Raymond James
Mark Breidenbach – H.C. Wainwright & Co.
Keith Markey, Scientific Director – Griffin Securities
Edward White, Senior Research Analyst – FBR Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Multiple development opportunities within the Company's Dermatology and Ophthalmology franchises
Leader in the development of advanced RNAi-based therapeutics
Broad and robust intellectual property portfolio
catalyst Calendar
RXI-109-1301: study to be completed in 2015
RXi Pharmaceuticals Corp. Content